Advertisement
Advertisement
U.S. Markets open in 9 hrs 12 mins
Advertisement
Advertisement
Advertisement
Advertisement

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0200+0.2000 (+24.39%)
At close: 04:00PM EDT
1.0000 -0.02 (-1.96%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8200
Open0.8545
Bid0.9800 x 900
Ask1.0000 x 29200
Day's Range0.8300 - 1.0270
52 Week Range0.6200 - 11.1800
Volume11,862,481
Avg. Volume1,914,048
Market Cap53.45M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals

    Raleigh drugmaker slashes workforce as biotech downturn deepens

    The drugmaker is cutting one-third of its U.S. commercial workforce as part of a plan to save $50 million. The move comes as the biotech industry sees cuts across the board as the highs of the pandemic fade away.

  • Benzinga

    RedHill Biopharma Shares Trading Higher On Improved Q1 Profitability

    View more earnings on RDHLSee more from BenzingaThe Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows PromiseDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • American City Business Journals

    Raleigh drugmaker pursuing Covid treatment raising $15M to fund acquisitions

    Additionally, the company agreed to issue unregistered private warrants to the investor to purchase up to more than 13 million shares at $1.48 a share in a concurrent private placement, according to a filing with the U.S. Securities and Exchange Commission. RedHill's stock fell more than 30 percent Monday after the company disclosed the offering prior to markets opening. The offering follows the company signing a licensing deal with the South Korean corporation Kubo Co. Ltd for the exclusive rights to commercialize RedHill's investigational Covid-19 treatment called opaganib.

Advertisement
Advertisement